Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
121 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Renal Anemia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Renal Anemia - Pipeline Review, H1 2015', provides an overview of the Renal Anemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Anemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Renal Anemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Renal Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Renal Anemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Renal Anemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Renal Anemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Renal Anemia Overview 9 Therapeutics Development 10 Pipeline Products for Renal Anemia - Overview 10 Pipeline Products for Renal Anemia - Comparative Analysis 11 Renal Anemia - Therapeutics under Development by Companies 12 Renal Anemia - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Renal Anemia - Products under Development by Companies 18 Renal Anemia - Companies Involved in Therapeutics Development 21 3SBio Inc. 21 Acceleron Pharma, Inc. 22 Akebia Therapeutics, Inc. 23 Amgen Inc. 24 Aprogen, Inc. 25 Bayer AG 26 BIOCAD 27 CCM Duopharma Biotech Bhd. 28 Daiichi Sankyo Company, Limited 29 Dong-A Socio Group 30 FibroGen, Inc. 31 GlaxoSmithKline plc 32 Hospira, Inc. 33 Intas Pharmaceuticals Ltd. 34 Japan Tobacco Inc. 35 JCR Pharmaceuticals Co., Ltd. 36 Jiangsu Hansoh Pharmaceutical Co., Ltd. 37 Medgenics Inc. 38 Myungmoon pharmaceutical Co.,Ltd. 39 Panacea Biotec Limited 40 Pieris AG 41 ProMetic Life Sciences Inc. 42 Sandoz International GmbH 43 Zydus Cadila Healthcare Limited 44 Renal Anemia - Therapeutics Assessment 45 Assessment by Monotherapy Products 45 Assessment by Target 46 Assessment by Mechanism of Action 48 Assessment by Route of Administration 50 Assessment by Molecule Type 52 Drug Profiles 54 AKB-6548 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 daprodustat - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 darbepoetin alfa - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 darbepoetin alfa - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 darbepoetin alfa - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 darbepoetin alfa - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 darbepoetin alfa - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 darbepoetin alfa (recombinant) - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 DS-1093 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 EPO-018B - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 epoetin alfa - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 epoetin alfa (recombinant) - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 epoetin zeta - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 FG-2216 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 FMX-8 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 JTZ-951 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 MDGN-201 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 MM-P01-01 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 molidustat - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 NuPIAO - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 PBI-1402 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 PBI-4050 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 PEG-EPO - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Peg-EPO - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 PRS-080 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Recombinant Protein for Renal Anemia - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 roxadustat - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 sotatercept - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Renal Anemia - Recent Pipeline Updates 93 Renal Anemia - Dormant Projects 110 Renal Anemia - Discontinued Products 111 Renal Anemia - Product Development Milestones 112 Featured News & Press Releases 112 Mar 27, 2015: Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 112 Mar 16, 2015: Akebia Announces Presentation of Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia at WCN 112 Mar 11, 2015: Bayer to Present Latest Clinical Data On Molidustat 114 Mar 10, 2015: Akebia Announces Completion of Enrollment in Phase 2 Trial of AKB-6548 in Dialysis Patients with Anemia Related to Chronic Kidney Disease 114 Oct 15, 2014: Medgenics Reports Positive Initial Clinical Data From Clinical Study Of MDGN-201 115 Sep 26, 2013: ProMetic's Lead Drug Candidate, PBI-4050, Enters Clinical Program 116 Sep 13, 2013: Approval of Additional Indication of Long-Acting Erythropoiesis-Stimulating Agent NESP for Pediatric Patients with renal anemia in Japan 116 Jul 31, 2013: Astellas and FibroGen Announce the Initiation of a Phase 2 Clinical Study in Japan of ASP1517/FG-4592 for Treatment of Anemia of Chronic Kidney Disease 117 Apr 16, 2013: Amgen To Pay US $24.9m To Resolve False Claims Act Allegations 117 Jan 16, 2013: Amgen Announces Top-Line Results Of Phase III Aranesp RED-HF Trial 118 Appendix 120 Methodology 120 Coverage 120 Secondary Research 120 Primary Research 120 Expert Panel Validation 120 Contact Us 120 Disclaimer 121
List of Tables Number of Products under Development for Renal Anemia, H1 2015 10 Number of Products under Development for Renal Anemia - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 13 Number of Products under Development by Companies, H1 2015 (Contd..1) 14 Comparative Analysis by Late Stage Development, H1 2015 15 Comparative Analysis by Clinical Stage Development, H1 2015 16 Comparative Analysis by Early Stage Development, H1 2015 17 Products under Development by Companies, H1 2015 18 Products under Development by Companies, H1 2015 (Contd..1) 19 Products under Development by Companies, H1 2015 (Contd..2) 20 Renal Anemia - Pipeline by 3SBio Inc., H1 2015 21 Renal Anemia - Pipeline by Acceleron Pharma, Inc., H1 2015 22 Renal Anemia - Pipeline by Akebia Therapeutics, Inc., H1 2015 23 Renal Anemia - Pipeline by Amgen Inc., H1 2015 24 Renal Anemia - Pipeline by Aprogen, Inc., H1 2015 25 Renal Anemia - Pipeline by Bayer AG, H1 2015 26 Renal Anemia - Pipeline by BIOCAD, H1 2015 27 Renal Anemia - Pipeline by CCM Duopharma Biotech Bhd., H1 2015 28 Renal Anemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 29 Renal Anemia - Pipeline by Dong-A Socio Group, H1 2015 30 Renal Anemia - Pipeline by FibroGen, Inc., H1 2015 31 Renal Anemia - Pipeline by GlaxoSmithKline plc, H1 2015 32 Renal Anemia - Pipeline by Hospira, Inc., H1 2015 33 Renal Anemia - Pipeline by Intas Pharmaceuticals Ltd., H1 2015 34 Renal Anemia - Pipeline by Japan Tobacco Inc., H1 2015 35 Renal Anemia - Pipeline by JCR Pharmaceuticals Co., Ltd., H1 2015 36 Renal Anemia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 37 Renal Anemia - Pipeline by Medgenics Inc., H1 2015 38 Renal Anemia - Pipeline by Myungmoon pharmaceutical Co.,Ltd., H1 2015 39 Renal Anemia - Pipeline by Panacea Biotec Limited, H1 2015 40 Renal Anemia - Pipeline by Pieris AG, H1 2015 41 Renal Anemia - Pipeline by ProMetic Life Sciences Inc., H1 2015 42 Renal Anemia - Pipeline by Sandoz International GmbH, H1 2015 43 Renal Anemia - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 44 Assessment by Monotherapy Products, H1 2015 45 Number of Products by Stage and Target, H1 2015 47 Number of Products by Stage and Mechanism of Action, H1 2015 49 Number of Products by Stage and Route of Administration, H1 2015 51 Number of Products by Stage and Molecule Type, H1 2015 53 Renal Anemia Therapeutics - Recent Pipeline Updates, H1 2015 93 Renal Anemia - Dormant Projects, H1 2015 110 Renal Anemia - Discontinued Products, H1 2015 111
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.